Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

NOVARTIS

Filed by BGR GOVERNMENT AFFAIRS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2025
Income
$60,000.00
Expenses
Not reported
Client
NOVARTIS
Filing UUID
0c201d8e-c2b5-4cd9-a5e4-4db1d2c0d9c9
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies

Literal federal measure citations: H.R.1672

MMM · Medicare/Medicaid

Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act

Literal federal measure citations: H.R.1672

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.